anaveon
  • About
    • Our Journey
    • About Us
    • Anaveon In Depth
  • Science
    • Our Approach
    • Publications
  • Team
    • Our Team
    • Our Board
    • Our Investors
  • News
  • Career
  • Contact Us
Select Page
HomeAuthor archive for admin
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma

Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma

by admin | Mar 16, 2023 | Press Releases

– OMNIA-2 is a Phase I/II study evaluating ANV419 as monotherapy and in combination with daratumumab, or lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma –   Basel, March 16, 2023 – Anaveon, a clinical stage,...
Anaveon appoints Dr Eduard Gasal as Chief Medical Officer

Anaveon appoints Dr Eduard Gasal as Chief Medical Officer

by admin | Nov 30, 2022 | Press Releases

Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dr Eduard Gasal as Chief Medical Officer (CMO).
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting

Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting

by admin | Nov 10, 2022 | Press Releases

Anaveon, a clinical stage, immuno-oncology company, today announced updated clinical data from the ongoing Phase I study of ANV419 in patients with solid tumors at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA
Anaveon announces upcoming poster presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

Anaveon announces upcoming poster presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

by admin | Oct 31, 2022 | Press Releases

Anaveon, a clinical stage, immuno-oncology company, today announced that it will present two posters on its lead program ANV419 at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA.
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

by admin | Sep 10, 2022 | Press Releases

– ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2R-beta-gamma selectivity – – A Phase II program of ANV419 has been initiated in Melanoma and multiple combination trials,...
« Older Entries

Search here

Categories

  • Press Releases 19
  • Uncategorized 1

Recent Posts

  • Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
    March 23, 2023
  • Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
    March 16, 2023
  • Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
    February 2, 2023

We are social

Popular Tags

#ANV419 #ESMO22 #phaseI/II 2020 AACR Annual Meeting anaveon brand clinical data CTA approval First patient investment news phase I phase I/II study phase II presentation press solid tumors start trial study data team website

Archives

  • March 2023  2
  • February 2023  1
  • November 2022  2
  • October 2022  1
  • September 2022  1
  • July 2022  3
  • April 2022  1
  • March 2022  1
  • December 2021  1
  • November 2021  1
  • June 2021  1
  • March 2021  1
  • November 2020  1
  • May 2020  1
  • April 2019  1
  • February 2019  1
Anaveon_ submark

Contact us

Email

contact@anaveon.com

Postal Address

Anaveon AG

Technologiepark Basel

Hochbergerstrasse 60C

4057 Basel

Switzerland

Follow us

  • Linkedin
  • Home
  • Privacy Policy
  • Photography Credit

© 2020 All Rights Reserved